

# Congo

Population 2015

4.6 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	2.3 (1.3–3.5)	49 (29–75)
Mortality (HIV+TB only)	2.4 (2–2.9)	53 (44–63)
Incidence (includes HIV+TB)	18 (11–25)	379 (246–542)
Incidence (HIV+TB only)	6.4 (3.9–9.5)	138 (84–205)
Incidence (MDR/RR-TB)**	0.67 (0.29–1)	15 (6.3–22)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	1 (0.5–1.5)	6.9 (3.6–10)	7.9 (4.1–12)
Males	0.92 (0.55–1.3)	8.7 (6–11)	9.6 (6.5–13)
Total	1.9 (1.3–2.6)	16 (12–19)	18 (11–25)

TB case notifications, 2015	
Total cases notified	10 119
Total new and relapse	9 937
- % tested with rapid diagnostics at time of diagnosis	3%
- % with known HIV status	13%
- % pulmonary	75%
- % bacteriologically confirmed among pulmonary	51%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	57% (40–88)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.28 (0.17–0.44)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	479	38%
- on antiretroviral therapy	164	34%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			300 (160–430)
Estimated % of TB cases with MDR/RR-TB	3.2% (1.4–5)	14% (6.9–21)	
% notified tested for rifampicin resistance		2015%	9 469
MDR/RR-TB cases tested for resistance to second-line drugs			5
Laboratory-confirmed cases		MDR/RR-TB: 41, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 13, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	69%	4 108
Previously treated cases, excluding relapse, registered in 2014	94%	182
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	3.8
Funding source: 12% domestic, 68% international, 20% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



Incidence  
Notified (new and relapse)  
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



New and relapse  
Retreatment, excluding relapse  
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)

